4CPS-020 Use, efficacy and adherence to treatment with PCKS9 inhibitors in real clinical practice

Background and importanceIn recent years innovative therapies have been developed for the treatment of hypercholesterolaemia that allow an effective decrease in low density lipoprotein (LDL)-cholesterol (LDL-c). These are alirocumab and evolocumab, anti-proprotein convertase subtilisin-kexin type 9...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2020-03, Vol.27 (Suppl 1), p.A56-A56
Main Authors: Claramunt García, R, Muñoz Cid, CL, Sánchez Ruiz, A, López, AM, Pérez Cano, E, Jimenez López, Y, Jerez Rojas, J
Format: Article
Language:English
Subjects:
Cholesterol
Clinical medicine
Patient compliance
Patients
Pharmacy
Statins
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and importanceIn recent years innovative therapies have been developed for the treatment of hypercholesterolaemia that allow an effective decrease in low density lipoprotein (LDL)-cholesterol (LDL-c). These are alirocumab and evolocumab, anti-proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibodies. The Pharmacy and Therapeutics Commission of our hospital has accepted the following indications: familial hypercholesterolaemia (HF) with LDL-c >100 mg/dL with maximum tolerated dose of statins, cardiovascular disease (CVD) established with LDL-c >100 mg/dL with maximum tolerated dose of statins and statin intolerant with LDL-c >100 mg/dL.Aim and objectivesTo study the correct use of PCSK9 inhibitors in real clinical practice in a third level hospital. To evaluate efficacy and adherence to treatment.Material and methodsThis was an observational, analytical and retrospective study of patients treated with anti-PCSK9 who attended the pharmacy service for a consultation. On 30 September 2019, a cross section was performed and the data collected were: sex, prescribed anti-PCKS9, dosage, theoretical and real dispensed units, indication and analytical data at 0 and 12 weeks (total cholesterol, LDL-c, high density lipoprotein cholesterol and triglycerides).ResultsA total of 82 patients (53 men, 29 women) were studied: 57(69.5%) patients received evolocumab and 25 (30.5%) alirocumab. The distribution by diagnoses were: 17.1% HF, 46.3% CVD, 13.3% statin intolerance and 15.8% other.After 12 weeks, the mean reduction in LDL-c was 54.3%, reaching the LDL-c target 80% was considered adherent. Only 8.5% of patients were below the established limit, and were non-adherent.Conclusion and relevancePCSK9 inhibitors are effective in decreasing LDL-c levels (
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2020-eahpconf.121